Irene Hunt

Title: Irene Hunt: Innovator in S1P Receptor Modulation

Introduction

Irene Hunt is a notable inventor based in Basel, Switzerland. She has made significant contributions to the field of medicine, particularly in the treatment of multiple sclerosis and other inflammatory disorders. With a total of 2 patents, her work focuses on innovative dosage regimens for S1P receptor modulators.

Latest Patents

Irene's latest patents include a dosage regimen of an S1P receptor modulator aimed at treating patients suffering from multiple sclerosis. This invention emphasizes the importance of testing patients for a history of infection caused by the varicella zoster virus and ensuring they are vaccinated prior to the administration of the modulator. Another patent also addresses a dosage regimen for S1P receptor modulators in the treatment of inflammatory or autoimmune disorders, specifically highlighting the need for patient vaccination before administering fingolimod or its pharmaceutically acceptable salts at a daily dosage of 0.5 mg.

Career Highlights

Throughout her career, Irene has worked with prominent companies, including Novartis AG. Her expertise in the pharmaceutical field has allowed her to develop groundbreaking treatments that enhance patient care and outcomes.

Collaborations

Irene has collaborated with notable professionals in her field, including Craig Boulton and Pascale Burtin. These partnerships have contributed to the advancement of her research and the successful development of her patents.

Conclusion

Irene Hunt's innovative work in S1P receptor modulation has made a significant impact on the treatment of multiple sclerosis and other autoimmune disorders. Her contributions continue to shape the future of medical treatments and patient care.